Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Clinician's Roundtable

Desvenlafaxine: The Newest Antidepressant

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    After many years of trying, Wyeth has received approval and is currently marketing the newest antidepressant in the US -- desvenlafaxine. What do you need to know about this medicine? Host Dr. Leslie Lundt welcomes Dr. Philip Ninan, vice president for Neuroscience Global Medical Affairs at Wyeth Pharmaceuticals to discuss the ins and outs of desvenlafaxine.

Recommended
Details
Presenters
Comments
  • Overview

    After many years of trying, Wyeth has received approval and is currently marketing the newest antidepressant in the US -- desvenlafaxine. What do you need to know about this medicine? Host Dr. Leslie Lundt welcomes Dr. Philip Ninan, vice president for Neuroscience Global Medical Affairs at Wyeth Pharmaceuticals to discuss the ins and outs of desvenlafaxine.

Schedule2 Dec 2024